Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Articular Bevacizumab for Recurrent Hemarthrosis in Hemophilia Patients With Chronic Synovitis
NCT07187661Completed
- Sponsor
- Khyber Medical University
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab in hemophilia A and synovitis, sponsored by Khyber Medical University. Primary endpoints: Annualized Bleeding Rate at 3 months, Hemophilia Joint Health Score at 12 months and 3 more. Started Sep 2025; status: completed.
02
Drugs
bevacizumab
03
Conditions
hemophilia Asynovitis
Beyond the preview
Go deeper on NCT07187661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187661.